Cited by 276Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Treatment

Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy

Open access
Wallace, Mark S., Marcotte, Thomas D., Umlauf, Anya, Gouaux, Ben, Atkinson, Joseph H.·2015·The Journal of Pain

Abstract

Unlabelled A randomized, double-blinded, placebo controlled crossover study was conducted in 16 patients with painful diabetic peripheral neuropathy to assess the short-term efficacy and tolerability of inhaled cannabis. In a crossover design, each participant was exposed to 4 single dosing sessions of placebo or to low (1% tetrahydrocannabinol [THC]), medium (4% THC), or high (7% THC) doses of cannabis. Baseline spontaneous pain, evoked pain, and cognitive testing were performed. Subjects were then administered aerosolized cannabis or placebo and the pain intensity and subjective "highness" score was measured at 5, 15, 30, 45, and 60 minutes and then every 30 minutes for an additional 3 hours. Cognitive testing was performed at 5 and 30 minutes and then every 30 minutes for an additional 3 hours. The primary analysis compared differences in spontaneous pain over time between doses using linear mixed effects models. There was a significant difference in spontaneous pain scores between doses (P < .001). Specific significant comparisons were placebo versus low, medium, and high doses (P = .031, .04, and <.001, respectively) and high versus low and medium doses (both P < .001). There was a significant effect of the high dose on foam brush and von Frey evoked pain (both P < .001). There was a significant negative effect (impaired performance) of the high dose on 2 of the 3 neuropsychological tests (Paced Auditory Serial Addition Test, Trail Making Test Part B.Perspective This small, short-term, placebo-controlled trial of inhaled cannabis demonstrated a dose-dependent reduction in diabetic peripheral neuropathy pain in patients with treatment-refractory pain. This adds preliminary evidence to support further research on the efficacy of the cannabinoids in neuropathic pain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpain.2015.03.008

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with painful diabetic peripheral neuropathy, different formulations of inhaled cannabis showed a significant dose-dependent effect on spontaneous pain score and allodynia.

    “A randomized, doubleblinded, placebo controlled study conducted in patients with painful diabetic peripheral neuropathy using different formulation of inhaled cannabis showed a significant dosedependent effect on spontaneous pain score and allodynia (Wallace et al, 2015).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., & Atkinson, J. H.
Affiliations
University of California San Diego (US)
Corresponding author
Wallace, Mark S.
Venue
The Journal of Pain
Publisher
Elsevier BV
Published
2015-07
Volume
16
Issue
7
Pages
616-627
ISSN
1526-5900 (ISSN-L)
OpenAlex
W2081629704
Cited by
276
References
55
Citations by year
2026: 14 · 2025: 42 · 2024: 31 · 2023: 21 · 2022: 35 · 2021: 23 · 2020: 19 · 2019: 22 · 2018: 36 · 2017: 19 · 2016: 11 · 2015: 3
FWCI
16.53
Type
journal article
Language
en
Open access
Locations
  • Journal of Pain (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (P30MH062512)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
inhaled cannabis, tetrahydrocannabinol, diabetic peripheral neuropathy, neuropathic pain, refractory pain, dose-dependent analgesia, spontaneous pain, evoked pain, cognitive impairment, tolerability, cannabinoids
MeSH terms
Administration, Inhalation, Aged, Analysis of Variance, Cognition, Depression, Diabetic Neuropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Pain Measurement, Dronabinol, Time Factors, Treatment Outcome, Cross-Over Studies, Analgesics, Non-Narcotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review